Riskpilot← Back to searchSign inGet full accessSpånga MedKonsult AB
ABActiveOrg 5591633390Torphagsvägen 54General medical practice activities · NACE 8621Est. 20181-4 employees
Revenue 2025
SEK 439K
-77% vs 2024
EBITDA margin
-19.6%
-128% vs 2024
Equity ratio
48.7%
Financial strength
Net profit 2025
SEK -92K
-139% vs 2024
| Revenue | SEK 439K | -77% |
| EBITDA | SEK -86K | -128% |
| Net profit | SEK -92K | -139% |
| Total assets | SEK 228K | -42% |
| Equity | SEK 111K | -61% |
| Employees | — | — |
Legal name
Spånga MedKonsult AB
Org number
5591633390
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
25 juni 2018
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Uthyrning av sig själv som läkare till primärvårdsmottagningar. Hyra ut sig själv som läkare till öppen vårdsmottagningar på sjukhus.Hyra ut sig själv som läkare till specialistmottagningar.
Address
Torphagsvägen 54
Email
nasrollah.delshad@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 48 | 153 | 1 908 | 439 |
| Staff expenses | — | −0 | — | — | — |
| EBITDA | −37 | 37 | 74 | 312 | −86 |
| Depreciation & amort. | −0 | — | −1 | −4 | −4 |
| EBIT | −37 | 37 | 73 | 308 | −90 |
| Net financials | — | 10 | −6 | −9 | −3 |
| Profit before tax | −37 | 47 | 67 | 299 | −92 |
| Tax | −0 | −1 | −16 | −66 | −0 |
| Net profit | −37 | 46 | 51 | 233 | −92 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 62 | 116 | 151 | 390 | 228 |
| Equity | 51 | 96 | 147 | 283 | 111 |
| Long-term debt | 0 | — | 0 | 38 | 32 |
| Short-term debt | 11 | 20 | 4 | 69 | 85 |
| Total debt | 11 | 20 | 4 | 107 | 117 |
EBITDA margin
-19.6%
This company
15.8%
Market median
-224% vs market
20212025
Equity ratio
48.7%
This company
38.2%
Market median
+27% vs market
20212025
Return on equity
-82.9%
This company
18.4%
Market median
-551% vs market
20212025
Net profit margin
-21.0%
This company
8.1%
Market median
-359% vs market
20212025
Asset turnover
1.93×
This company
1.12×
Market median
+72% vs market
20212025
Debt / equity
1.05×
This company
0.62×
Market median
-69% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Spånga MedKonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Shaker Nasrollah | Board of Directors | 0 companies |
| Delshad Nasrollah | Chairman | 0 companies |
| Amir Nasrollah | Deputy Board Member | 0 companies |